The $1.55B upfront cash infusion dramatically de-risks Edgewise's cardiovascular pipeline and provides a clean balance sheet. The stock should re-rate on the cash value alone — the implied cash per share is substantial relative to the current market cap. Key catalysts ahead: CIRRUS-HCM Part D data (Q2 2026) and GRAND CANYON Becker data (Q4 2026) which triggers a $200M milestone. Monitor HSR clearance timeline.
Price Chart
Executive Summary
Edgewise Therapeutics announced an asset purchase agreement to sell its neuromuscular program, including the sevasemten compound, to Servier for $1.55 billion in upfront cash, plus up to $1.1 billion in regulatory and commercial milestones. The transaction transforms Edgewise into a cardiovascular-focused company, with proceeds expected to fully fund EDG-7500 development through potential approval. The deal is expected to close in Q3 2026, subject to HSR clearance and customary conditions.
Key Financial Metrics
Key Facts
- Edgewise sells sevasemten and related neuromuscular assets to Servier for $1.55 billion upfront cash.
- Potential milestone payments up to $1.1 billion: $200M or $100M for Becker approval, $600M for Duchenne approval, $300M for sales milestone.
- Proceeds fully fund EDG-7500 development through potential approval and strengthen the balance sheet.
- Edgewise becomes a pure-play cardiovascular company focused on EDG-7500 (Phase 2 HCM), EDG-15400 (Phase 1 HFpEF), and EDG-003 (preclinical).
- Transaction approved by both boards; expected to close in Q3 2026 subject to HSR clearance.
- Edgewise to report 12-week CIRRUS-HCM Part D data in Q2 2026.
Financial Impact
$1.55 billion upfront cash plus up to $1.1 billion in milestones, versus a pre-announcement market cap of $3.7B (upfront alone represents ~42% of market cap in cash).
Risk Factors
- HSR regulatory delay or unexpected antitrust issues could push closing beyond Q3 2026.
- Milestone payments are contingent on FDA approvals and commercial sales — not guaranteed.
- Post-transaction, Edgewise's valuation depends entirely on early-stage cardiovascular pipeline (EDG-7500, EDG-15400) with no approved products.
- CIRRUS-HCM Phase 2 data risk — if 12-week results are weak, the remaining pipeline thesis is undermined.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249951 |
| Document: d24037dex991.htm | 0001193125-26-249951 |
| Document: 0001193125-26-249951-index-headers.html | 0001193125-26-249951 |
| Document: 0001193125-26-249951-index.html | 0001193125-26-249951 |
| Document: 0001193125-26-249951.txt | 0001193125-26-249951 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 14, 2026 7w ago | Insider Cluster | $44.17 $44.62 | ▲ +1.02% | ▲ +3.01% | $41.22 (−6.68%) |
Aug 6, 2026 8w ago | 8-K | $44.42 $41.95 | ▼ −5.56% | ▼ −6.16% | $41.22 (−7.20%) |
Jul 13, 2026 11w ago | 8-K | $41.27 $44.58 | ▲ +8.02% | ▲ +4.84% | $41.22 (−0.12%) |
Jun 1, 2026 17w ago | 8-K | $40.26 $40.63 | ▲ +0.92% | ▲ +2.22% | $41.22 (+2.38%) |
May 7, 2026 21w ago | 8-K | $35.58 $36.21 | ▲ +1.77% | ▼ −1.37% | $41.22 (+15.85%) |
Apr 23, 2026 23w ago | DEFA14A | $31.58 $32.69 | ▲ +3.51% | ▼ −0.51% | $41.22 (+30.53%) |
Mar 27, 2026 26w ago | 144 | $30.28 $30.99 | ▲ +2.34% | ▼ −10.25% | $41.22 (+36.13%) |
Feb 26, 2026 31w ago | 8-K | $29.66 $31.65 | ▲ +6.71% | ▲ +13.11% | $41.22 (+38.98%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access